Tecan Group (1TECN) Stock Overview
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
1TECN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeTecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 144.10 |
| 52 Week High | CHF 167.00 |
| 52 Week Low | CHF 125.60 |
| Beta | 1.01 |
| 1 Month Change | -0.69% |
| 3 Month Change | -3.93% |
| 1 Year Change | -15.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1TECN | IT Life Sciences | IT Market | |
|---|---|---|---|
| 7D | 12.3% | 6.5% | 3.2% |
| 1Y | -15.2% | -10.0% | 23.9% |
Return vs Industry: 1TECN underperformed the Italian Life Sciences industry which returned -10% over the past year.
Return vs Market: 1TECN underperformed the Italian Market which returned 23.9% over the past year.
Price Volatility
| 1TECN volatility | |
|---|---|
| 1TECN Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.2% |
| 10% least volatile stocks in IT Market | 3.1% |
Stable Share Price: 1TECN has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1TECN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,166 | Monica Manotas | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution.
Tecan Group AG Fundamentals Summary
| 1TECN fundamental statistics | |
|---|---|
| Market cap | €1.80b |
| Earnings (TTM) | -€120.83m |
| Revenue (TTM) | €963.64m |
Is 1TECN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1TECN income statement (TTM) | |
|---|---|
| Revenue | CHF 882.48m |
| Cost of Revenue | CHF 571.64m |
| Gross Profit | CHF 310.84m |
| Other Expenses | CHF 421.49m |
| Earnings | -CHF 110.65m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 11, 2026
| Earnings per share (EPS) | -8.83 |
| Gross Margin | 35.22% |
| Net Profit Margin | -12.54% |
| Debt/Equity Ratio | 13.1% |
How did 1TECN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 21:13 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harry Gillis | Berenberg |
| Delphine Le Louet | Bernstein |
| Susannah Ludwig | Bernstein |